New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pravastatin sodium 10mg;   - tablet - 10 mg - active: pravastatin sodium 10mg   excipient: croscarmellose sodium iron oxide yellow lactose monohydrate light magnesium oxide magnesium stearate microcelac 100 povidone - pravastatin is indicated: · in hypercholesterolemic patients without clinically evident coronary heart disease, as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. · for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. · as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease. · coronary artery disease: in patients with a history of either a myocardial infarction or unstable angina pectoris to reduce the risk for total mortality, chd death, recurrent coronary event (including myocardial infarction), need for myocardial revascularisation procedures, and need for hospitalisation. · cerebrovascular disease: in patients with a history of coronary artery disease (i.e. either a myocardial infarction or unstable angina pectoris) to reduce the risk of stroke or transient ischemic attacks (tias). · cardiac and renal transplantation: in patients receiving immunosuppressive therapy to improve survival in cardiac transplant patients and to reduce the risk of acute rejection in kidney transplant patients

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pravastatin sodium 20mg;   - tablet - 20 mg - active: pravastatin sodium 20mg   excipient: croscarmellose sodium iron oxide yellow lactose monohydrate light magnesium oxide magnesium stearate microcelac 100 povidone - pravastatin is indicated: · in hypercholesterolemic patients without clinically evident coronary heart disease, as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. · for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. · as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease. · coronary artery disease: in patients with a history of either a myocardial infarction or unstable angina pectoris to reduce the risk for total mortality, chd death, recurrent coronary event (including myocardial infarction), need for myocardial revascularisation procedures, and need for hospitalisation. · cerebrovascular disease: in patients with a history of coronary artery disease (i.e. either a myocardial infarction or unstable angina pectoris) to reduce the risk of stroke or transient ischemic attacks (tias). · cardiac and renal transplantation: in patients receiving immunosuppressive therapy to improve survival in cardiac transplant patients and to reduce the risk of acute rejection in kidney transplant patients

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pravastatin sodium 40mg;   - tablet - 40 mg - active: pravastatin sodium 40mg   excipient: croscarmellose sodium iron oxide yellow lactose monohydrate light magnesium oxide magnesium stearate microcelac 100 povidone - pravastatin is indicated: · in hypercholesterolemic patients without clinically evident coronary heart disease, as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. · for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. · as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease. · coronary artery disease: in patients with a history of either a myocardial infarction or unstable angina pectoris to reduce the risk for total mortality, chd death, recurrent coronary event (including myocardial infarction), need for myocardial revascularisation procedures, and need for hospitalisation. · cerebrovascular disease: in patients with a history of coronary artery disease (i.e. either a myocardial infarction or unstable angina pectoris) to reduce the risk of stroke or transient ischemic attacks (tias). · cardiac and renal transplantation: in patients receiving immunosuppressive therapy to improve survival in cardiac transplant patients and to reduce the risk of acute rejection in kidney transplant patients

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; ethylcellulose; titanium dioxide; povidone; macrogol 6000; hypromellose; purified talc; magnesium stearate; iron oxide red - for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; povidone; ethylcellulose; crospovidone; purified talc; iron oxide red; titanium dioxide; hypromellose; lactose monohydrate - for the treatment of hypertension.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - efavirenz 600mg;  ; emtricitabine 200mg;  ; tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil - film coated tablet - active: efavirenz 600mg   emtricitabine 200mg   tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil excipient: colloidal silicon dioxide croscarmellose sodium hyprolose low-substituted hydroxypropylcellulose, lh 11 iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 85f540043 sodium metabisulfite - indicated for the treatment of hiv infected adults over the age of 18 years, alone or in combination with other antiretroviral agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ambrisentan 10mg - film coated tablet - 10 mg - active: ambrisentan 10mg excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry pink 85f540046 purified water - indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ambrisentan 5mg - film coated tablet - 5 mg - active: ambrisentan 5mg excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry pink 85f540046 purified water - indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - folic acid 5mg - tablet - 5 mg - active: folic acid 5mg excipient: crospovidone lactose magnesium stearate maize starch povidone - the treatment of megaloblastic anaemia when folate deficiency is identified as the exclusive cause. folate deficiency is a consequence of inadequate dietary intake, malabsorption, or increased utilisation in conditions such as pregnancy, lactation, haemolyticanaemia, hyperthyroidism, exfoliative dermatitis, and chronic infection. prophylaxis of folate deficiency resulting from renal dialysis, pregnancy and lactation when the mother is malnourished, and chronic haemolytic states such as thalassaemia major or sickle-cell anaemia. label claim: treatment of megaloblastic anaemia due to folate deficiency. prevention of folate deficiency.

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris limited - atorvastatin calcium trihydrate - film-coated tablet - hmg coa reductase inhibitors; atorvastatin